Junior biotech organizations have been obtaining more interest this year. Recently, Boehringer Ingelheim’s shopping spree continued with a EUR210m takeover of ViraTherapeutics, an oncolytic virus specialist it has been working with since 2016.
The privately-held German drug maker was targeting the investment with ViraTherapeutics’ lead candidate VSV-GP, a cancer therapy that works by infecting tumors with a virus that both destroys malignant cells directly and mobilizes an immune response against them.
In addition, German biotech Affimed has previously agreed to deal with Roche’s Genentech to discover new cancer immunotherapies with an amazing $5 billion-dollar deal.
A few stocks to look at include: CEL-SCI Corporation (CVM), Roche Holdings, Inc. (RHHBY), Affirmed N.V. (AFMD), and Marinus Pharmaceuticals, Inc. (MRNS)
Market Cap: $105.57M, Share Price: $3.86
CEL-SCI Corporation announced that the company has received $5,435,367 through the exercise of warrants to purchase shares of the Company’s common stock during August through September 13, 2018. As of September 13, 2018, CEL-SCI had 27,351,324 outstanding shares of common stock.
Roche Holdings, AG.
Market Cap: $207B Share Price: $30.68
Mentioned above, Roche is the parent company to Genentech, which is host to the potential $5 billion dollar deal. The company is currently facing concerns in the UK regarding the pricing of its MS drug.
Market Cap: $265.15M Share Price: $4.25
Affirmed is the company Roche made the deal with and the stock has consolidated a bit since its large jump following the news.
Marinus Pharmaceuticals, Inc.
Market Cap: $283.67M Share Price: $7.00
Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, CEO, Christopher M. Cashman, recently presented a company overview at the Baird 2018 Healthcare Conference.